The effect of RhoA and proteasome inhibitor MG132 on angiogenesis in tumors

Journal of Sichuan University (Medical Science)

Volumn 42, Issue 4, 2011, Pages 445-450

  Yue, Cai Xia ^a   Ma, Ji ^b   Zhou, Hai Jun ^a   Tang, Qiu Lin ^a   Li, Li Lan ^a   Bi, Feng ^a   Xue, Yan ^b  

^a SICHUAN UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

RhoA MVD HIF 1 MG132

Indexed keywords

EID: 80051533136     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Feldser D, Agani F, Iyer NV, et al. Reciprocal positive regulation of hypoxia-inducible factor 1 alpha and insulin-like growth factor 2. Cancer Res, 1999;59(16):3915-3918. (Pubitemid 29393552)
2. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res, 2003;63(5):1138-1143. (Pubitemid 36278449)
3. Ridley AJ. Rho GTPases and cell migration. J Cell Sci, 2001;114(15):2713-2722. (Pubitemid 32785451)
4. Sherr CJ, Roberts JM. CDK inhibitors: positive and negativeregulators of G12 phase progression. Genes Dev, 1999;13(12):1501-1512. (Pubitemid 29297917)
5. Pervaiz S, Cao J, Chao OS, et al. Activation of the Rac GTPase inhibits apoptosis in human tumor cells. Oncogene
6. Ghosh K, Thodeti CK, Dudley AC, et al. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. PNAS, 2008;105(32):11305-11310.
7. Xue Y, Bi F, Zhang X, et al. Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF-1α activation. Int J Cancer, 2006;118(12):2965-2972.
8. Haase VH. The VHL tumor suppressor! master regulator of HIF. Curr Pharm Des, 2009;15(33):3895-3903.
9. Sorokin AV, Kim ER, Ovchinnikov LP. Proteasome system of protein degradation and processing. Biochemistry (Moscow), 2009;74(13):1411-1442.
10. Zhou J H, Ye F, Chen H Z, et al. Altered expression If cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma. Life Sci, 2006;78(22):2643-2649.
11. Weidner N. Intratumo microvessel density as a prognostic factor in cancer. Am J Pathol, 1995;1147(1):9-19.
12. Chen D, Li M, Luo J, et al. Direct interactions between HIF-1a and Mdm2 modulate p53 function. J Biol Chem, 2003;278(16):13595-13598. (Pubitemid 36799889)
13. Hayashi M, Sakata M, Takeda T, et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha expression through RhoA activation in trophoblast cells. J Clin Endocrinol Metab, 2005;90(3):1712-1719. (Pubitemid 40464043)
14. Feijôo-Cuaresma M, Méndez F, Maqueda A, et al. Inadequate activation of the GTPase RhoA contributes to the lack of fibronectin matrix assembly in von Hippel-Lindau proteindefective renal cancer cells. J Biol Chem; 2008;283(36):24982-24990.
15. Birle DC, Hedley DW. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res, 2007;67(4):1735-1743. (Pubitemid 46383400)
16. Schmid T, Zhou J, Kohl R, et al. p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1(HIF-1). Biochem J, 2004;380 (Pt 1):289-295. (Pubitemid 38725754)
17. Minnema MC, van der Spek E, van de Donk NW, et al. New developments in the treatment of patients with multiple myeloma. Neth J Med, 2010;68(1):24-32.